EMA Fails to Follow Legislation and Its Own Policy, page-16

yes there was no in the study standard care comparison, but he patients were characterised, and fall into the known to be hard (unlikely to get better group) long term sufferers. With complications IIRC. So lots of power in that, even though the design is simple.
Not good enough for public release may be your opinion, doesn't seem to be the prevailing standard.

Did a google search on 'vitronectin safety concerns'
lots of stuff, but the first hits were about theraputic use of embryonic stem cells, the next most highyl rated hit was your post above...
I didn't find specific paper or pages on the implict risks inherent in vitronectin at all,
do you have a more focussed set of search terms?

Nope diff state, and not associated in any way except shares, which i could sell out of at gain if I chose to.
So yeah only my money voluntarily on the table based on my judgement.

but DYOR.


I do gotta say for how negative you are on "short: that's just not good enough for public release."
are you sure your sentiment is hold.